Loading...
01/10 15:52
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals mixed signals: strong product launches and cost savings are offset by cash decline and adoption challenges. Financial performance shows revenue growth and reduced losses, but declining gross margins and cash reserves are concerning. The Q&A section highlights adoption hurdles and cash constraints, but also potential recovery in payments. Overall, the sentiment is neutral, with no strong catalysts to suggest a significant stock price movement.
Commercial Revenue $18.4 million, up 21% year-over-year. The growth was driven by the broadening deployment of the RECELL system, particularly RECELL GO, and contributions from new products like Cohealyx and PermeaDerm, as well as expansion from burn centers to trauma centers. However, sequential revenue was flat due to a temporary headwind caused by delays in Medicare and Medicaid Services' implementation of new CPT codes, which affected provider reimbursement and demand.
Gross Profit Margin 81.2%, down from 86.1% in the same period in 2024. The decrease was mainly due to product mix, a higher inventory reserve, and other adjustments. The gross margin for RECELL products alone was 84.3%.
Operating Expenses $26.1 million, down from $28.7 million in the same period in 2024. This decline was mainly due to a $2 million reduction in sales and marketing costs and a $0.8 million reduction in G&A expenses, offset slightly by a $0.2 million increase in R&D expenses.
Net Loss $9.9 million, a 36% improvement from the net loss of $15.4 million in the same period in 2024. This improvement was attributed to reduced operating expenses and other income gains.
Cash and Marketable Securities $15.7 million as of June 30, 2025, compared to $35.9 million at December 31, 2024. The decline reflects the company's cash usage during the period.
RECELL System: Commercial revenue for Q2 2025 was $18.4 million, up 21% YoY. However, sequential revenue was flat due to reimbursement delays from Medicare contractors, impacting demand. RECELL demonstrated a 36% reduction in hospital stays for burn patients, confirmed by a real-world analysis of over 6,300 patients.
Cohealyx: Launched in April 2025, Cohealyx demonstrated graft readiness in 5-10 days, faster than competitors. It has gained traction with pending Value Analysis Committee approvals in 25% of U.S. burn centers. July sales included a $300,000 order from a single account.
PermeaDerm: Featured in 10 presentations at U.S. burn conferences, PermeaDerm acts as a temporary biosynthetic dressing. It is being evaluated in a study comparing its cost and clinical outcomes to allograft.
RECELL GO mini: Designed for smaller wounds (480 square cm or smaller), RECELL GO mini aims to expand adoption in outpatient settings.
U.S. Market Expansion: RECELL is used in nearly all U.S. burn centers and is expanding into Level 1 and 2 trauma centers. CMS approved a New Technology Add-on Payment (NTAP) for RECELL in trauma wounds, effective October 1, 2025.
International Expansion: CE Mark approval for RECELL in the EU and Australia is delayed to Q4 2025. A lean distributor-led model is planned for these markets.
Sales Organization Restructuring: Reduced field headcount from 108 to 82, saving $2.5 million per quarter and $10 million annually. Shifted focus from service to sales orientation.
Financial Adjustments: Revised 2025 revenue guidance to $76-$81 million from $100-$106 million due to reimbursement delays. Adjusted OrbiMed credit agreement to lower revenue covenants for the next four quarters.
Outcome-Based Business Model: Introduced agreements where hospitals receive rebates if RECELL does not achieve targeted reductions in hospital stays. Two centers have adopted this model, potentially increasing RECELL usage by 150 patients per month each.
Portfolio Integration: Positioned RECELL, Cohealyx, and PermeaDerm as a comprehensive wound care solution, emphasizing faster healing, better outcomes, and lower costs.
Reimbursement Delays: The Centers for Medicare and Medicaid Services (CMS) and Medicare Administrative Contractors (MACs) delayed the implementation of new CPT codes for RECELL, leading to claims processing issues. This caused uncertainty in provider reimbursement, reducing demand for RECELL by approximately 20% in the first half of 2025.
Revenue Forecast Reduction: Due to reimbursement disruptions, the company lowered its 2025 financial forecast, reflecting a significant impact on revenue and delaying free cash flow and profitability targets to 2026.
Credit Agreement Amendments: The company had to secure a waiver and amend its credit agreement with OrbiMed, adjusting revenue covenants and issuing equity as compensation, indicating financial strain.
International Launch Delays: Bureaucratic delays in CE Mark approval have postponed the EU and Australia launch of RECELL, impacting international revenue growth.
Gross Margin Decline: The overall gross margin decreased due to product mix changes and higher inventory reserves, which could affect profitability.
Sales Organization Restructuring: The company reduced its sales team from 108 to 82 people, saving $2.5 million per quarter but potentially impacting sales coverage and customer engagement.
Cash and Marketable Securities Decline: Cash and marketable securities dropped from $35.9 million at the end of 2024 to $15.7 million as of June 30, 2025, necessitating additional capital raising to support working capital needs.
Product Adoption Challenges: Despite clinical success, the adoption of RECELL and other products like Cohealyx and PermeaDerm faces hurdles such as Value Analysis Committee (VAC) approvals and competitive pressures.
2025 Financial Forecast Adjustment: The company has lowered its 2025 financial forecast due to reimbursement disruptions but expects a rebound in the second half of the year as payment issues are resolved.
RECELL Demand Recovery: Demand for RECELL is expected to pick up during the third and fourth quarters of 2025 as reimbursement issues are resolved.
Revenue Guidance for 2025: Revised full-year 2025 commercial revenue guidance to $76 million to $81 million, indicating a growth of approximately 19% to 27% compared to 2024.
Free Cash Flow and Profitability: The company now expects to start generating free cash flow in Q2 2026 and achieve GAAP profitability in Q3 2026, delayed from earlier projections of late 2025.
New Technology Add-on Payment (NTAP): CMS approval for NTAP for RECELL in trauma wounds and hospitalized patients, effective October 1, 2025, expected to drive increased utilization in the inpatient setting.
RECELL GO Mini Launch: The launch of RECELL GO Mini, optimized for smaller wounds, is expected to broaden adoption in outpatient settings.
International Expansion: CE Mark approval for RECELL in the EU and Australia is delayed to Q4 2025, with plans for a distributor-led commercial model upon approval.
Cohealyx and PermeaDerm Growth: Cohealyx and PermeaDerm are expected to contribute significantly to revenue growth, with Cohealyx showing strong early demand and PermeaDerm expanding its applications.
Outcome-Based Business Model: The company is implementing an outcomes-based partnership model for RECELL, which could significantly increase revenue in participating facilities.
The selected topic was not discussed during the call.
The earnings call presents a mixed outlook. Financial performance showed a revenue decline and reduced margins, but cost management improved the operating loss and net loss. The Q&A reveals management's focus on U.S. growth, reimbursement normalization, and resource allocation challenges. However, lowered 2025 guidance, under-penetration, and lack of clear European strategy weigh on sentiment. Despite some positives like reduced expenses and cash position improvement, the overall sentiment remains neutral due to mixed guidance and uncertainties in execution.
The earnings call reveals mixed signals: strong product launches and cost savings are offset by cash decline and adoption challenges. Financial performance shows revenue growth and reduced losses, but declining gross margins and cash reserves are concerning. The Q&A section highlights adoption hurdles and cash constraints, but also potential recovery in payments. Overall, the sentiment is neutral, with no strong catalysts to suggest a significant stock price movement.
The earnings call presents a mixed outlook. While there is strong revenue growth and optimistic guidance for 2025, the company missed EPS expectations and faces regulatory and cash flow risks. The Q&A highlighted positive product developments but also uncertainties in revenue contributions. Operating expenses are high, and there is no shareholder return plan. Given these factors, the stock price reaction is likely to be neutral, as positive growth drivers are offset by financial and operational concerns.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
